Clinical trial · Observational
The Value of 68Ga-FAPI PET/CT in Preoperative Evaluation of Thyroid Cancer with Lymph Node Metastases
NCT06730529CI-TRIAL-00083638recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to investigate the value of 68Ga-FAPI in the preoperative evaluation of thyroid cancer of different pathologic types.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Patients diagnosis of thyroid cancer with lymph node metastases
Primary outcomes (1)
- measure
- Clinical staging of thyroid cancer with lymph node metastasis
- timeFrame
- Within 1 week after enrollment
- description
- The value of 68Ga-FAPI PET/CT in the evaluation of thyroid cancer with lymph node metastases in clinical staging
Secondary outcomes (2)
- measure
- Standardized uptake value(SUV)
- timeFrame
- Within 1 week after enrollment
- description
- SUV of 68Ga-FAPI uptake on PET/CT images for tumor lesions
- measure
- Disease free survival
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Pathological and clinical diagnosis of thyroid cancer with lymph node metastases. 2. Signed and dated informed consent form. 3. Commitment to comply with research procedures and co-operation in the implementation of the full research process. 4. Aged 16-80 years old. Exclusion Criteria: 1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc. 2. Intestinal perforation, complete intestinal obstruction. 3. Pregnant women and women who may be pregnant, women who are breastfeeding. 4. Non-compliant person.
References
Publications (0)
Data not yet available
No reference posted for this study.